13F Holdings
中文EN

CVKD Cadrenal Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1937993 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY29.8%
TTM EPS YoY57.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-358.3%
ROA-267.9%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets16.0%
Debt / equity0.00x
Current ratio6.26x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.96x
Accruals ratio-10.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20082008-03-31
Income statement
Revenue—————
Cost of revenue——$220,095—$220,095
R&D expense$4.10M$4.21M$4.08M$392,859$200,000
SG&A expense$9.35M$6.75M$3.55M$2.31M—
Operating income-$13.46M-$10.96M-$7.63M-$2.70M—
Interest expense——$3,534$40,192—
Pretax income-$13.24M-$10.65M-$8.36M-$6.71M—
Net income-$13.24M-$10.65M-$8.36M-$6.71M—
EBITDA-$13.45M-$10.96M-$7.63M-$2.70M—
EPS (basic)-6.64-8.73-9.29-0.85—
EPS (diluted)-6.64-8.73-9.29-0.85—
Dividends declared per share16.5016.50———
Weighted avg. shares (diluted)1.99M1.22M899,4657.89M—
Balance sheet
Cash & equivalents$4.01M$10.02M$8.40M$32,586—
Current assets$4.32M$10.11M$8.49M$727,596—
PP&E, net$5,174$6,944$2,287$1,013—
Total assets$4.33M$10.12M$8.52M$778,174—
Current liabilities$1.59M$2.68M$826,875$1.33M—
Short-term debt———$597,068—
Total liabilities$1.59M$2.68M$826,875$6.33M—
Shareholders' equity$2.74M$7.44M$7.69M-$5.55M—
Shares outstanding2.34M1.78M868,1848.19M—
Cash flow statement
Operating cash flow-$12.60M-$7.36M-$3.53M-$1.20M—
Capital expenditure$5,104$6,537$3,254$2,279—
Free cash flow-$12.61M-$7.36M-$3.53M-$1.21M—
Investing cash flow-$5,104-$6,537-$3,254-$2,279—
Financing cash flow$6.60M$8.98M$11.90M$1.24M—
Depreciation & amortization$6,874$1,880$1,980$1,266—
Stock-based compensation$1.94M$1.42M$710,381$928,049—

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.